Lineage Cell Therapeutics: Q3 Earnings Insights
Portfolio Pulse from Benzinga Insights
Lineage Cell Therapeutics (AMEX:LCTX) reported Q3 earnings with an EPS of $-0.04, in line with estimates. However, revenue was down $1.75 million from the same period last year. Last quarter, the company beat EPS estimates, which led to a 2.13% increase in the share price the next day.
November 09, 2023 | 9:35 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Lineage Cell Therapeutics reported Q3 earnings in line with estimates, but with a significant drop in revenue compared to last year. This could potentially impact the stock negatively in the short term.
While the company met EPS estimates, the significant drop in revenue compared to the same period last year could be a cause for concern among investors. This could potentially lead to a decrease in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100